Search

Influenza A virus A/Minnesota/41/2019 (H3N2) recombinant hemagglutinin antigen

Vaccines provide protection from influenza by exposing the immune system to the virus (or parts of the virus) which stimulates an immunological defence against future exposure to the virus, or "antigen … that it was previously exposed to.

Influenza B virus B/Washington/02/2019 recombinant hemagglutinin antigen

Vaccines provide protection from influenza by exposing the immune system to the virus (or parts of the virus) which stimulates an immunological defence against future exposure to the virus, or "antigen … that it was previously exposed to.

Influenza A virus A/Nebraska/14/2019 (H1N1) antigen (MDCK cell derived, propiolactone inactivated)

Vaccines provide protection from influenza by exposing the immune system to the virus (or parts of the virus) which stimulates an immunological defence against future exposure to the virus, or "antigen … that it was previously exposed to.

Influenza A virus A/Hong Kong/2671/2019 NIB-121 (H3N2) antigen (formaldehyde inactivated)

Vaccines provide protection from influenza by exposing the immune system to the virus (or parts of the virus) which stimulates an immunological defence against future exposure to the virus, or "antigen … that it was previously exposed to.

Influenza A virus A/Hong Kong/2671/2019 (H3N2) live (attenuated) antigen

Vaccines provide protection from influenza by exposing the immune system to the virus (or parts of the virus) which stimulates an immunological defence against future exposure to the virus, or "antigen … that it was previously exposed to.

Ensitrelvir

Ensitrelvir is under investigation in clinical trial NCT05605093 (Strategies and Treatments for Respiratory Infections & Viral Emergencies (STRIVE): Shionogi Protease Inhibitor (Ensitrelvir)).

Influenza B virus B/Michigan/01/2021 antigen (formaldehyde inactivated)

These vaccines provide protection from influenza by exposing the immune system to the virus (or parts of the virus) which results in an immunological defense against future exposure to the virus, or "antigen … Inactivated vaccines contain a virus particle that has been grown in media and then subsequently killed, or inactivated, through exposure to heat or chemicals such as formaldehyde.

Chromium gluconate

Chromium nicotinate

Fianlimab

Fianlimab is under investigation in clinical trial NCT06190951 (A Trial to Learn if Fianlimab and Cemiplimab Are Safe and Work Better Than Anti-pd1 Alone in Adult Participants With Resectable Stage 3 or